Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, has closed its previously announced overnight marketed public offering. In connection with the offering, the company issued an aggregate of 24,264,706 units of the company, each…Read More
InvestorNewsBreaks Cybin Inc NYSE American CYBN NEO CYBN Announces Closing of Marketed Public Offering
